This trial is evaluating whether E7820 will improve 1 primary outcome in patients with Myelodysplastic Syndromes. Measurement will happen over the course of 1 year.
This trial requires 38 total participants across 1 different treatment group
This trial involves a single treatment. E7820 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"The current American College of Hematology recommendations for the treatment of acute myeloid leukemia are derived largely from the results of the 1976 Intergroup HODG (International Working Party on Leukemia and Lymphomas) report. The recommended therapy for AML was a combination of cytarabine, daunorubicin, and idarubicin, or alternatively, high-dose methotrexate followed by six cytotoxic drugs. A first line regimen of mitoxantrone plus etoposide followed by autologous stem cell transplantation was recommended only for young adults. Treatment of CML included mitoxantrone plus prednisone and vincristine." - Anonymous Online Contributor
"The side effects of e7820 were similar to those of placebo in our patient population. Patients receiving e7820 experienced greater reductions in blood counts than did those receiving placebo. E7820 does not appear to have a significant effect on bone marrow function." - Anonymous Online Contributor
"Chronic lymphocytic leukemia not responsive to two chemotherapies was resistant to a third regimen. The overall survival rate was significantly higher in patients who received more than 8 cycles of chemotherapy. Data from a recent study show that chemotherapy can cure chronic leukemia, particularly when repeated courses are given. However, the most important outcome is the development of long-term remissions. Those patients who benefitted from longer treatments will have a greater chance of achieving this goal, while others will continue to progress to the next stage of disease." - Anonymous Online Contributor
"[Leukemia, myelomonocytic, chronic and [acute lymphoblastic leukemia](https://www.withpower.com/clinical-trials/acute-lymphoblastic-leukemia)s, acute], [myelomonocytic, chronic] are all very serious cancers. The chance of developing leukemia, myelomonocytic, chronic increases with age, and those who have high blood counts (high white blood cell count) have an increased chance of developing leukemia, myelomonocytic, chronic. It is important that all people, especially those with high blood counts, should get screened every year for leukemia, myelomonocytic, chronic." - Anonymous Online Contributor
"Data from a recent study show that the compound e7820 has similar efficacy (IC50 = 7.5 nM) as imatinib mesylate in a model of Bcr-Abl-dependent human chronic myelogenous leukemia cells expressing the T315I mutation in Abl kinase domain. This observation suggests that e7820 might be useful in treating patients carrying this aberrant mutation who have not responded to imatinib mesylate." - Anonymous Online Contributor
"E7820 was well tolerated and was associated with an acceptable safety profile when administered at the approved dose. People who were treated with E7820 had low rates of serious adverse events." - Anonymous Online Contributor
"The World Health Organization classification has been commonly used in scientific research to classify cancers. This classification system yields information on prognosis and treatment for specific types of cancer. However, this system does not capture the complexity of leukemias, which are heterogenous diseases with different genetic mutations and response to therapy. The American Cancer Society classifies leukemias into acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). Although AML accounts for about 90% of cases of leukemia, CLL is more common than AML. The current classification system may hinder the understanding of disease progression and treatment outcomes." - Anonymous Online Contributor
"The treatments for [acute lymphoblastic leukemia](https://www.withpower.com/clinical-trials/acute-lymphoblastic-leukemia) (ALL), non-Hodgkin's lymphoma (NHL), and myeloid leukemia, myelomonocytic, chronic (M4) have all improved considerably over the past decade. There are new discoveries though, specifically for ALL. Notably, the newly discovered drug CCRCC-2 inhibits the growth of blasts. CCRCC-2 was initially developed as a treatment for hepatitis B virus infection. Because of its ability to inhibit the multiplication of cancer cells, it has been used to treat some patients who had previously been considered ineligible for standard therapy. For ALL, CCRCC-2 works synergistically with other anticancer therapies." - Anonymous Online Contributor
"E7820 was found to be generally well tolerated but was associated with significant toxicity at high doses; this may explain why it has been largely replaced by more efficacious drugs in clinical practice. The role of E7820 in myeloid malignancies has yet to be thoroughly explored." - Anonymous Online Contributor
"The latest research on leukemia, myelomonocytic, chronic explains how the bone marrow sits within the body and why it’s crucial for survival. In order to provide proper care, it is important to understand the various types of blood cell disorders as well as their potential treatments. The National Institutes of Health (NIH) provides information about leukemia, myelomonocytic, chronic through the details of research findings and clinical trials. [Power (http://www.withpower.com/research-and-findings/leukemia-myelomonocytic-chronic) advises that you explore the different types of leukemias and investigate the possible cures." - Anonymous Online Contributor